CN101360720A - 新颖的2-氨基嘧啶酮衍生物及其用途 - Google Patents

新颖的2-氨基嘧啶酮衍生物及其用途 Download PDF

Info

Publication number
CN101360720A
CN101360720A CNA200680051085XA CN200680051085A CN101360720A CN 101360720 A CN101360720 A CN 101360720A CN A200680051085X A CNA200680051085X A CN A200680051085XA CN 200680051085 A CN200680051085 A CN 200680051085A CN 101360720 A CN101360720 A CN 101360720A
Authority
CN
China
Prior art keywords
alkyl
heterocyclylalkyl
aryl
arylalkyl
heteroarylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680051085XA
Other languages
English (en)
Chinese (zh)
Inventor
杰弗里·艾尔伯特
唐纳德·安迪西克
菲尔·爱德华兹
马克·西尔维斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
AstraZeneca AB
Original Assignee
Astex Therapeutics Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd, AstraZeneca AB filed Critical Astex Therapeutics Ltd
Publication of CN101360720A publication Critical patent/CN101360720A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA200680051085XA 2005-11-15 2006-11-13 新颖的2-氨基嘧啶酮衍生物及其用途 Pending CN101360720A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73732605P 2005-11-15 2005-11-15
US60/737,326 2005-11-15

Publications (1)

Publication Number Publication Date
CN101360720A true CN101360720A (zh) 2009-02-04

Family

ID=38048893

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680051085XA Pending CN101360720A (zh) 2005-11-15 2006-11-13 新颖的2-氨基嘧啶酮衍生物及其用途

Country Status (5)

Country Link
US (1) US20090215801A9 (enExample)
EP (1) EP1951680A4 (enExample)
JP (1) JP2009515949A (enExample)
CN (1) CN101360720A (enExample)
WO (1) WO2007058580A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
MX2010013256A (es) 2008-06-13 2010-12-21 Shionogi & Co Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
CA2777739A1 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
EA023350B1 (ru) 2009-10-16 2016-05-31 Мелинта Терапьютикс, Инк. Противомикробные соединения, способы их получения и применение
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
EP2747769B1 (en) 2011-08-22 2017-08-02 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
EP2773207B1 (en) * 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
KR20160070066A (ko) 2013-09-09 2016-06-17 멜린타 테라퓨틱스, 인크. 항균 화합물, 및 이의 제조 방법 및 이용 방법
SG11201707346RA (en) 2015-03-11 2017-10-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EP3452479A1 (en) 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625026A (en) * 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1261327B1 (en) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
US6777420B2 (en) * 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
US20030114445A1 (en) * 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
AU2002950853A0 (en) * 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2153832B1 (en) * 2003-12-15 2016-03-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
AR054619A1 (es) * 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
JP2008543841A (ja) * 2005-06-14 2008-12-04 シェーリング コーポレイション 大環状複素環式アスパルチルプロテアーゼインヒビター
US7763606B2 (en) * 2005-10-27 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2009513670A (ja) * 2005-10-31 2009-04-02 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター

Also Published As

Publication number Publication date
US20090215801A9 (en) 2009-08-27
EP1951680A1 (en) 2008-08-06
JP2009515949A (ja) 2009-04-16
EP1951680A4 (en) 2011-08-10
US20080255164A1 (en) 2008-10-16
WO2007058580A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
CN101360720A (zh) 新颖的2-氨基嘧啶酮衍生物及其用途
CN101360714A (zh) 新颖的可用于治疗Aβ相关病理的2-氨基-杂环
AU2007261749B2 (en) Substituted isoindoles as bace inhibitors and their use
CN101360716A (zh) 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
JP2008516945A (ja) 置換されたアミノ化合物およびそれらの使用
CN101460480A (zh) 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
JP2008516946A (ja) 置換されたアミノ−ピリミドンおよびそれらの使用
JP2009520022A (ja) 置換２−アミノピリミジン−４−オン、その薬学的組成物並びにＡβ関連病状の処置及び／又は予防におけるその使用
CN101360721A (zh) 新颖的2-氨基嘧啶酮衍生物或2-氨基吡啶酮衍生物及其用途
CN101360722A (zh) 新颖的2-氨基嘧啶衍生物及其用途
CN101506162B (zh) 作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途
HK1127035A (en) Novel 2-aminopyrimidinone derivatives and their use
HK1127036A (en) Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
HK1127034A (en) Novel 2-aminopyrimidine derivatives and their use
HK1127038A (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1127035

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090204

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1127035

Country of ref document: HK